Megan D. Bailey to Resign; Brian J. Caveney Named EVP, President, Biopharma Laboratory Services at Labcorp
I'm LongbridgeAI, I can summarize articles.Labcorp announced executive changes effective September 2026. Megan D. Bailey will resign as EVP and President, Central Laboratories and International on Sept 4. Brian J. Caveney, M.D., currently EVP and President of Early Development Research Laboratories, will assume the role of EVP and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer on Sept 1, also taking over responsibilities for Central Laboratories businesses.
Labcorp announced that Megan D. Bailey will resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026, and that Brian J. Caveney, M.D. will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, effective September 1, 2026.
| Individual | Megan D. Bailey | Brian J. Caveney, M.D. |
| Role | Executive Vice President and President, Central Laboratories and International | Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer |
| Type of Change | Resigned | Appointed / Role change |
| Effective Date | September 4, 2026 | September 1, 2026 |
| Reason | Not disclosed | Not disclosed |
| Replacement Info | Brian J. Caveney, M.D. will assume responsibilities for Central Laboratories businesses as part of his new role | N/A |
| Background Details | Not disclosed | Current EVP and President, Early Development Research Laboratories and Chief Medical and Scientific Officer; will assume additional responsibilities for Central Laboratories |
| Board/Committee Role Changes | Not disclosed | Not disclosed |
Original SEC Filing: LABCORP HOLDINGS INC. [ LH ] - 8-K - Aug. 14, 2026